Adrian (Ad) Rawcliffe

Adrian (Ad) Rawcliffe is the Chief Executive Officer of Adaptimmune, a company focused on cell therapy for cancer treatment.48 He assumed this role in 2019, succeeding James Noble as the company's CEO.6

Professional Background

Rawcliffe has extensive experience in the biotechnology and pharmaceutical industries, particularly in the field of cell therapy. He is known for his leadership in developing innovative approaches to cancer treatment using T cell products.4

Areas of Expertise

Cell Therapy:: Rawcliffe is deeply involved in the development and commercialization of cell therapies for cancer treatment. He has been instrumental in advancing Adaptimmune's approach to off-the-shelf T cell products.4

Business Leadership:: As CEO, he oversees the company's strategic direction, including the establishment of new franchises and the expansion of commercial teams.5

Recent Activities

• In early 2024, Rawcliffe presented Adaptimmune's plans for the year at the J.P. Morgan Healthcare Conference.7
• He has been actively involved in recruiting key personnel, such as welcoming Cintia Piccina to lead the commercial team for Adaptimmune's sarcoma franchise.5

Personal Interests

Outside of his professional role, Rawcliffe has shown interest in supporting scientific education. In 2023, he used his LinkedIn network to seek laboratory work opportunities for his son, demonstrating his personal commitment to fostering scientific passion in the younger generation.3

Adrian Rawcliffe maintains an active presence on LinkedIn, where he frequently shares updates about Adaptimmune's progress and developments in the field of cell therapy for cancer treatment.12